Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease

Abstract

BackgroundSome recent studies have suggested that beta-blocker use in patients with chronic obstructive pulmonary disease (COPD) is associated with a reduction in the frequency of acute exacerbations. However, the long-term effects of beta-blocker use on lung function of COPD patients have hardly been evaluated.Patients and methodsWe retrospectively reviewed 31 Japanese COPD patients taking beta-blockers for >1 year and 72 patients not taking them. The association between beta-blocker use and the annual change in forced expiratory volume in 1 second (FEV1) was assessed.ResultsAt baseline, patient demographic characteristics were as follows: 97 males (mean age 67.0±8.2 years); 32 current smokers; and Global Initiative for Chronic Obstructive Lung disease (GOLD) stages I: n=26, II: n=52, III: n=19, and IV: n=6. Patients taking beta-blockers exhibited a significantly lower forced vital capacity (FVC), FEV1, and %FVC, and a more advanced GOLD stage. The mean duration of beta-blocker administration was 2.8±1.7 years. There were no differences in the annual change in FEV1 between patients who did and did not use beta-blockers (−7.6±93.5 mL/year vs −4.7±118.9 mL/year, P=0.671). After controlling for relevant confounders in multivariate analyses, it was found that beta-blocker use was not significantly associated with the annual decline in FEV1 (β=−0.019; 95% confidence interval: −0.073 to 0.036; P=0.503).ConclusionLong-term beta-blocker use in Japanese COPD patients might not affect the FEV1, one of the most important parameters of lung function in COPD patients.

Reactive Oxygen Species and Antioxidative Defense in Chronic Obstructive Pulmonary Disease

“…The factors affecting the development and progression of COPD include genetic factors, age, sex, lung growth and development, exposure to particles, socioeconomic status, asthma and airway hyperresponsiveness, chronic bronchitis, and infections [3,5,6]. Among the related particles, cigarette smoke is the most commonly encountered risk factor for COPD [3].…”

Association of asthma–chronic obstructive pulmonary disease overlap syndrome with coronary artery disease, cardiac dysrhythmia and heart failure: a population-based retrospective cohort study

“…Previous studies suggest a beneficial effect of beta-blockers on AE in mild to moderate COPD. 14 15 However, benefits are less obvious in severe COPD and coexistent CVDs. 15 The role of beta-blockers 14 (eg, β1-adrenoceptor blockers) in AE-COPD with CAD, CD and HF, such as in elderly with severe cases, 15 is still being debated.…”

Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison

“…A recent single RCT including COPD patients without an indication for beta-blockers (therefore those with HF, previous MI or revascularization) failed to demonstrate clear benefits of metoprolol over placebo. Observational studies have included a more varied breadth of specific beta-blockers, however they do not present a clear picture: the population-based Rotterdam Study [ 71 ] reported significant decreases in FEV1 associated with both cardio and non-cardioselective beta-blockers, while two other studies, one from Scotland [ 35 ] and an one from Japan [ 72 ] reported no significant difference in FEV1. Yet, these results may be affected by confounding by indication, which may explain the variability of estimates.…”